Abstract 3608
Background
Based on results of the phase 2 BOLT study (NCT01327053), sonidegib 200 mg once daily (QD) was approved in the US for patients with locally advanced basal cell carcinoma (laBCC) not amenable to curative surgery or radiotherapy and in Switzerland and Australia also for metastatic BCC (mBCC). Here we report the final 42-month results—the longest follow-up data available from a hedgehog inhibitor (HHI) clinical trial—for a preplanned prespecified subgroup analysis for the primary endpoint, the objective response rate (ORR), in patients receiving 200 mg.
Methods
BOLT was a double-blind phase 2 study where HHI treatment–naïve patients with laBCC not amenable to curative surgery/radiotherapy, or with metastatic BCC (mBCC) were randomized 1:2 to sonidegib 200 or 800 mg QD, respectively. The primary endpoint was ORR. Analyses were performed at 12, 30, and 42 months after the last patient was randomized.
Results
For prespecified groups at 42 months, the ORRs for 200 mg QD were consistent for laBCC aggressive (59.5%; n = 37) and laBCC nonaggressive (51.7%; n = 29) histologies; male (43.8%; n = 48) and female (54.8%; n = 31); patients aged <65 years (59.4%; n = 32) and those aged ≥65 years (40.4%; n = 47); white (49.3%; n = 71) and nonwhite patients (37.5%; n = 8); and for patients not receiving (51.8%; n = 56) and those receiving (39.1%; n = 23) gastric pH agents. Subgroup analyses by disease strata (laBCC [56.1%; n = 66] vs mBCC [7.7%; n = 13]) and Eastern Cooperative Oncology Group performance status (0 [60%; n = 50] vs ≥ 1 [29.6%; n = 27;]) for the primary ORR endpoint showed heterogeneous results like those reported at 30 months. The safety/tolerability profile was consistent across 42 months with no new AEs emerging.
Conclusions
These results confirmed the consistency of treatment effect for sonidegib 200 mg QD at 42 months across several preplanned subgroups, including age, disease histology, gender, race, and use of gastric pH agents.
Clinical trial identification
NCT01327053.
Legal entity responsible for the study
Sun Pharmaceuticals Ltd.
Funding
Sun Pharmaceuticals Ltd.
Editorial Acknowledgement
Leonard Lionnet, PhD, CMPP of Lev Medical Communications provided medical writing support for this abstract.
Disclosure
R. Dummer: Consultant: Novartis Pharmaceuticals, Sun Pharma.
Resources from the same session
4104 - Lung cancer predisposition in women with previous breast cancer identified by whole exome sequencing
Presenter: Francesco Grossi
Session: Poster display session: Basic science, Endocrine tumours, Gastrointestinal tumours - colorectal & non-colorectal, Head and neck cancer (excluding thyroid), Melanoma and other skin tumours, Neuroendocrine tumours, Thyroid cancer, Tumour biology & pathology
Resources:
Abstract
2080 - Discordance of the PAM50 intrinsic subtypes compared with IHC-based surrogate in breast cancer patients: Potential implication of genomic alterations of discordance
Presenter: Yeon Hee Park
Session: Poster display session: Basic science, Endocrine tumours, Gastrointestinal tumours - colorectal & non-colorectal, Head and neck cancer (excluding thyroid), Melanoma and other skin tumours, Neuroendocrine tumours, Thyroid cancer, Tumour biology & pathology
Resources:
Abstract
4877 - Impact of Invasive Lobular Carcinoma in Latin American Breast Cancer Patients’ Disease-Free Survival. The new paradox.
Presenter: Diana Flores-Díaz
Session: Poster display session: Basic science, Endocrine tumours, Gastrointestinal tumours - colorectal & non-colorectal, Head and neck cancer (excluding thyroid), Melanoma and other skin tumours, Neuroendocrine tumours, Thyroid cancer, Tumour biology & pathology
Resources:
Abstract
2778 - Clinical validation of a NGS-based assay for the detection of BRCA1 and BRCA2 variants in Chinese patients with breast cancer or ovarian cancer
Presenter: Guanshan Zhu
Session: Poster display session: Basic science, Endocrine tumours, Gastrointestinal tumours - colorectal & non-colorectal, Head and neck cancer (excluding thyroid), Melanoma and other skin tumours, Neuroendocrine tumours, Thyroid cancer, Tumour biology & pathology
Resources:
Abstract
1877 - Correlation beetween the expression of androgens receptor (RA) and histopathological characteristics and survival parameters of breast cancer
Presenter: Irene Sillero
Session: Poster display session: Basic science, Endocrine tumours, Gastrointestinal tumours - colorectal & non-colorectal, Head and neck cancer (excluding thyroid), Melanoma and other skin tumours, Neuroendocrine tumours, Thyroid cancer, Tumour biology & pathology
Resources:
Abstract
1618 - Metabolic Syndrome in Breast Cancer Patients: An Observational Study
Presenter: Siddhant Khare
Session: Poster display session: Basic science, Endocrine tumours, Gastrointestinal tumours - colorectal & non-colorectal, Head and neck cancer (excluding thyroid), Melanoma and other skin tumours, Neuroendocrine tumours, Thyroid cancer, Tumour biology & pathology
Resources:
Abstract
1673 - The prognostic value of different molecular subtypes of breast cancer in relation to Enhancer-of-zeste homologue 2 expression
Presenter: Zohreh Sanaat
Session: Poster display session: Basic science, Endocrine tumours, Gastrointestinal tumours - colorectal & non-colorectal, Head and neck cancer (excluding thyroid), Melanoma and other skin tumours, Neuroendocrine tumours, Thyroid cancer, Tumour biology & pathology
Resources:
Abstract
3334 - A guided and personnalized treatment in metastatic breast cancer: optimisation of gene and protein expression in tumor tissue.
Presenter: Emmanuel Seront
Session: Poster display session: Basic science, Endocrine tumours, Gastrointestinal tumours - colorectal & non-colorectal, Head and neck cancer (excluding thyroid), Melanoma and other skin tumours, Neuroendocrine tumours, Thyroid cancer, Tumour biology & pathology
Resources:
Abstract
766 - HER2 staining intensity has prognostic impact on patients with HER2 type invasive breast cancer
Presenter: Hu Yi-Hsuan
Session: Poster display session: Basic science, Endocrine tumours, Gastrointestinal tumours - colorectal & non-colorectal, Head and neck cancer (excluding thyroid), Melanoma and other skin tumours, Neuroendocrine tumours, Thyroid cancer, Tumour biology & pathology
Resources:
Abstract
2841 - Does the minimal axillary approach lead to lose of prognostic factors in breast cancer?
Presenter: Rogerio de Araujo
Session: Poster display session: Basic science, Endocrine tumours, Gastrointestinal tumours - colorectal & non-colorectal, Head and neck cancer (excluding thyroid), Melanoma and other skin tumours, Neuroendocrine tumours, Thyroid cancer, Tumour biology & pathology
Resources:
Abstract